TABLE 3

Analysis of exacerbations

Exacerbation rate patient−1·year−1#Rate ratio (95% CI)Effect size#
ErdosteinePlacebo+Difference versus placebo %p-value§
Overall0.911.130.81 (0.68–0.92)−19.40.01
ICS use0.931.160.80 (0.67–0.94)−19.50.02
No ICS use0.891.100.81 (0.65–0.93)−19.30.01

ICS: inhaled corticosteroid. #: Poisson regression estimates; : n=215; +: n=230; §: two-sided p-value for between-treatment difference (significance level <5%, Wilcoxon rank-sum test).